AstraZeneca enters an exclusive global license agreement with China’s Dizal Pharmaceutical for the development and commercialisation of Zegfrovy, a lung cancer treatment. Under the terms described by the companies and reported by outlets, Dizal grants AstraZeneca worldwide rights to develop and market the drug. Dizal is set to receive an upfront payment of $600 million, followed by milestone payments that can total up to $900 million. One report also characterises the overall deal value as potentially reaching up to $1.5 billion, consistent with the combination of the upfront and milestone amounts. In addition to payments tied to milestones, Dizal receives tiered royalties on global sales of Zegfrovy, linking additional compensation to commercial performance. The agreement is presented as a global exclusive arrangement, meaning AstraZeneca holds exclusive rights across markets covered by the deal for Zegfrovy’s development and commercialisation. Financial details are presented in the sources, while specific regulatory plans and development timelines are not included in the provided excerpts.